 |
|
Нарушения когнитивных функций при тревожных расстройствах и депрессии
Заключение
Библиография
1. Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2003. – 319 С.
2. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. //Под ред. Н.Н.Яхно. –М. -2002. -86С.
3. Дамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. В кн.: «Болезни нервной системы. Руководство для врачей» / Под ред. Н.Н. Яхно. - М. Медицина, 2005. - Т.1. - С. 231-302.
4. Захаров В.В., Яхно Н.Н. Нарушения памяти. М.: изд-во «Геотар-Мед». -2001. -160С.
5. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). //Неврологический журнал. –2006. –Т.11. –С.27-32.
6. Захаров В.В., Вознесенская Т.Г. Нервно-психические нарушения: диагностические тесты. Москва: МЕДпресс-информ. -2013. –320 С.
7. Междунаpодная статистическая класcификация болезней и пpоблем, связанных со здоpовьем. Десятый пеpесмотp. (МКБ-10). — Женева, 1995
8. Лурия А.Р. Высшие корковые функции. Изд. 2. Москва: издательство МГУ. -1969.
9. Неверовский Д.В., Случевская С.Ф., Парфенов В.А. Дифференциальный диагноз дисциркуляторной энцефалопатии в амбулаторной практике // Неврология, нейропсихиатрия и психосоматика 2013 - № 2 – С. 38-42.
10. Парфенов В.А., Старчина Ю.А., Яхно Н.Н. Эпросартан (теветен) в профилактике повторного инсульта и когнитивных нарушений // Неврологический журнал, 2007, № 1, с. 46-51.
11. Парфенов В.А., Замерград М.В., Мельников О.А. Головокружение: диагностика и лечение, распространенные диагностические ошибки. М., МИА, 2009 – 152 с.
12. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М., МИА, 2012 – 288 с.
13. Преображенская И.С., Яхно Н.Н. Сосудистые когнитивные нарушения: клинические проявления, диагностика, лечение.// Неврологический журнал. –2007. –Т.12. -№5. –С.45-50.
14. Старчина Ю.А., Парфенов В.А., Чазова И.Е., Пустовитова Т.С., Яхно Н.Н. Когнитивные расстройства у пациентов с артериальной гипертензией // Журнал неврологии и психиатрии - 2008. - N.4. -С.39-43
15. Табеева Г.Р., Азимова Ю.Э. Мультимодальная стратегия нейропротекции при инсульте: результаты российской многоцентровой клинико-эпидемиологической программы СОКОЛ (Сравнительная Оценка эффективности Кавинтона и Общепринятых схем Лечения пациентов, перенесших острое нарушение мозгового кровообращения). Журнал Неврологии и Психатрии. -2012. –№.12. –Вып.2. –С.20-30.
16. Толмачева В.А., Парфенов В.А Причины головокружения у пациентов с артериальной гипертензией и его лечение // Врач – 2007. - № 4 – С. 49-53.
17. Херман В.М, Бон-Щлчевский В.Дж., Кунту Г. Инфузионная терапия актовегином у пациентов с первичной дегенеративной деменцией типа Альцгеймера и мульти-инфарктной деменцией (Результаты проспективного плацебо контролируемого двойного слепого исследования у пациентов, находящихся в условиях стационара). //Русский медицинский журнал. –2002. –Т.10. –N.15. –С.658-663.
18. Хомская Е.Д. Нейропсихология. 4ое издание. С-Пб: изд-во «ПИТЕР». -2005. -496С.
19. Чуканова Е.И. Эффективность кавинтона в лечении пациентов с хронической недостаточностью мозгового кровообращения. Российская многоцентровая клинико-эпидемиологическая программа «КАЛИПСО». Журнал Неврологии и Психиатрии. -2010. –№.12. –С.49-52.
20. Шмидт Е.В. Классификация сосудистых поражений головного и спинного мозга //Журнал невропатологии и психиатрии -1985. – N 9. - С. 1281-1288.
21. Янсен В., Брукнер Г.В. Лечение хронической цереброваскулярной недостаточности с использованием драже актовегин-форте (двойное слепое плацебо контролируемое исследование). //Русский медицинский журнал. –2002. –Т.10. -№.12-13. –С.543-546.
22. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 1: двигательные нарушения. //Неврол.журн. –2001. –Т.6. -№.2. –С.10-16.
23. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: когнитивные нарушения. //Неврол.журн. –2001. –Т.6, № 3. –С.10-19.
24. Яхно Н.Н. Когнитивные расстройства в неврологической практике // Неврологический журнал –2006. – Приложение № 1. – С.4-12.
25. Яхно Н.Н., Захаров В.В., Локшина А.Б., Коберская Н.Н., Мхитарян Э.А.Деменции: руководство для врачейМ., 2010 – 264 с.
26. Aarsland, D., Andersen K., Larsen J.P. et al. Risk of dementia in Parkinson’s disease. A community-based, prospective study. Neurology. -2001. –V.56. –P.730-736.
27. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. // Neurology 2007;68:1800-1808.
28. Akil M., Brewer G.J. Psychiatric and behavioral abnormalities in Wilson’s disease. // In: “Behavioral neurology of movement disorders”. W.J.Weiner, A.E.Lang (eds). Adv Neurol. –V.65. NY: Raven Press. –1995. –P.171-178.
29. Albert M.L. Subcortical dementia. In : Alzheimer's disease : Senile Dementia and Related Disorders. -New York, Raven Press, 1978, V.7, pp 173-180.
30. Alexopoulos G.S., Meners B.S., Young R.C. et al. ≪Vascular depression≫ hypothesis. //Arch Gen Psychiatry -1997. –V.54. –P.915–922.
31. Altieri M., Di Piero V., Pasquini M. Delayed poststroke dementia: a 4-year follow-up study. // Neurology. 2004; 62:2193-2197.
32. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results // J Neurol Sci. 2012; 322:96-101.
33. Amieva H., Meillon C., Helmer C. et al. Ginkgo Biloba Extract and Long-Term Cognitive Decline: A 20-Year Follow-Up Population-Based Study // PLOS ONE 2013; 8: e52755.
34. Atri A, Shaughessy LW, Locascia JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer’s disease. // Alxheimer Dis Assoc Disord. 2008;22:209–221.
35. Ballard C, Hanney ML, Theodoulou M. et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. // Lancet Neurol 2009; 8:151–157.
36. Baskys A., Hou A.C. Vascular dementia: pharmacological treatment and perspectives. Clin Interv Aging, 2007, V.2. N. 3. –P.327-335
37. Barbagallo S. G, Barbagallo M, Giordano M, et al. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial // Ann N Y Acad Sci. 1994; 717:253-269.
38. Barnes D. E., Blackwell T., Stone K. L. et al. Cognition in older women: the importance of daytime movement // Journal of the American Geriatrics Society, 2008; 56:1658–1664.
39. Barker W.W., Luis C.A., Kashuba A. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. // Alzheimer Dis. Assoc. Disord. ― 2002. ― Vol.16, N4. ― p.203 ― 212.
40. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
41. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia // Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003120.
42. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer’s disease. // Ann Pharmacother 2005;39:2073-2080.
43. Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O'Brien J., Ames D., Gustafson L. Et al.-Martin Dunitz-2004
44. Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. //J Neurosci. 1992;12:4427–4436.
45. Chen N., Yang M., Guo J. et al. Cerebrolyzin for VaD. Cochrane Database Syst Rev. -2013. -CD008900.
46. Colcombe S., Kramer A. F. Fitness effects on the cognitive function of older adults: a meta-analytic study // Psychological Science, 2003; 14:125–130.
47. DeKosky S.T.,Williamson J.D., Fitzpatrick A.L. et al.Ginkgo biloba for prevention of dementia: a randomized controlled trial //JAMA. 2008; 300:2253-2262
48. De Craen AJM, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidalantiinflammatory drug use and risk of dementia. // Am J Epidemiol 2005;161:114-120.
49. Del Parigi A., Panza F., Capurso C., Solfrizzi V. Nutritional factors, cognitive decline, and dementia // Brain Research Bulletin, 2006; 69:1–19.
50. DeKosky ST, Williamson JD, Fitzpatrick AL, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial // JAMA. 2008;300:2253-2262.
51. DiCarlo A., Lamassa M., Baldereschi M. et al. CIND and MCI in the Italien elderly: frequency, vascular risk factors, progression to dementia. //Neurology. -2007. –V.68. –N.22. –P.1909-1916.
52. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. -200. –V.55. –P.1621-1626.
53. Dubois B., Touchon J., Portet F. et al. The 5 words test: a simple and sensitive test for the diagnosis of Alzheimer’s disease. Presse Med. -2002. –V.31. –N.36. –P.1696-1699.
54. Dubois B., Feldman H.H., Jacova C. et al. Research criteria for the diagnosis of Alzheimer’s disease: revising of the NINCDS-ADRDRA criteria. //Lancet Neurol. -2007. –V.6. –N.8. –P.734-746.
55. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. // Lancet. 2007;369:208–216.
56. Emre M., Aarsland D., Albanese A. и соавт. Rivastigmine for dementia associated with Parkinson’s disease. //New Engl J Med. -2004. –V.351. –P.2509-2518.
57. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack // Cerebrovasc Dis.2008; 25: 457-507.
58. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? // J NeurolSci 2005;229-230:151-155.
59. Feldman H.H., Ferris S. Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. //Lancet Neurol. -2007. –V.6. –N.6. –P.501-512.
60. Fioravanti M, Flicker L. Nicergoline for dementia and other associated forms of cognitive impairment. Cochrane Database phils and auto-oxidation of brain tissue. Rinsho Syst Rev 2001; (4): CD003159
61. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly // Cochrane Database Syst Rev. 2005 Apr 18; (2):CD000269.
62. Fisher P., Jungwirth S., Zehetmayer S. et al. Conversion of subtypes of mild cognitive impairment to Alzheimer’s disease. //Neurology. -2007. –V.68. –N.4. –P.288-291.
63. Folstein M.F., S.E.Folstein, P.R.McHugh. Mini-Mental State: a practical guidefor grading the mental state of patients for the clinician. //J Psych Res. –1975. -V.12. –P.189-198.
64. Ganguli M., Dodge H.H., Shen C., DeKosky S.T. Mild cognitive impairment, amnestic type: an epidemiological study. //Neurology. -2004. –V.63. –P.115-121.
65. Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. // Curr Psychiatry Rep. 2010; 12:20-27.
66. Gorelick P. B., Scuteri A., Black S.E. et al. Vascular Contributions to Cognitive Impairment and Dementia : A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association // Stroke. 2011;42: 2672-2713.
67. Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease. // Dement Geriatr Cogn Disord. 2009;27:164–172.
68. Growdon J.S., Corkin S., Huff J., Rosen T.J.// Piracetam combined with lecitin in treatment of AD. // Neurobiol.Aging. -1986. –V.7. –Р.269-76.
69. Hanninen T., Hallikainen M., Toumainen S. et al. Prevalence of mild cognitive impairment: a pupulation based study in elderly subjects. //Acta Neurologica Scandinavica. -2002. –V.106. –P.148-154.
70. Hachinski V. Vascular dementia: radical re-definition. In Vascular dementia: ethiology, pathogenesis and clinical aspects. //Ed. By L.A.Carlson, S.G.Gottfries, B.Winblad. –Basel ETC: S.Karger. –1994. –P.2-4.
71. Hardy J. Towards Alzheimer’s therapy based on genetic knowledge. //Annu Rev Med. -2004. –V.55. –P.15-25.
72. Heart Protection Study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomisedplacebocontrolled trial. // Lancet. 2002;360:7–22.
73. Heiss R. //Effect of piracetam on cerebral glucose metabolism in AD as measured by PET. // J Cereb Blood Flow Metab. -1988. –V.8. –Р.613-617.
74. Hendrie H.C. Epidemiology of dementia and Alzheimer’s disease. //J Am Psych. -1998. –V.6. –PS3-S18.
75. Iqbal K., B.Winblad, T.Nishumura, N.Takeda, H.Wishewski (eds). Alzheimer's disease: biology, diagnosis and therapeutics. //J.Willey and sons ltd. -1997. –Р.831.
76. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. // Lancet Neurol. 2007;6:782–792.
77. Kivipelto M., Helkala E.L., Laakso M. et al. Middle life vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. //Br Med J. -2001. –V.322. –P.14447-1451.
78. Krishnan K.R.R., Hays J.C., Blazer D.G. MRI-defined vascular depression //Am J Psychiatry. -1997. –V.154. –P.497–501.
79. Jellinger K.A. Neuropathological diagnosis of Alzheimer’s disease. //J Neural Neurotrasm. -1998. –V.53 (suppl.). –P.97-118.
80. Larson E. B., Wang L., Bowen J. D. et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older // Annals of Internal Medicine, 2006; 144:73–81.
81. Larrieu S, Letenneur L, Helmer C, et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. // J Nutr Health Aging 2004;8:150-154
82. Lezak M.D. Neuropsychology assessment. NY: University press. –P.788.
83. Lopez O.L., Jagust W.J, DeKosky S.T. et al. Prevalence and classification of mild cognitive impairment in the cardiovascular health study cognition study. //Arch Neurol. -2003. –V.60. –P.1385-1389.
84. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. // J Neurol Neurosurg Psychiatry. 2009;80:600–607.
85. Lorentz W.J., Scanlan J.M., Borson S. Brief screening tests for dementia. //Can J Psych. -2002. –V.47. –N.8. –P.723-733.
86. Mannly J.J., Tang M.X., Schupf N. et al. Frequency and course of mild cognitive impairment in multiethnic community. //Ann Neurol. -2008. –V.63. –N.4. –P.494-506.
87. McKahn G., D.Drachman, M.Folstein et al. Clinical diagnosis of Alzheimer's disease: Report of NINCDS ADRDA Work group under the ausices of Department of Health and Human Services Task Force on Alzheimer's disease. //Neurology. –1984. -V.34. –939-944.
88. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. // Ann Intern Med 2005;142:37-46.
89. Morris M. C., Evans D. A., Tangney C. C. et al. Associations of vegetable and fruit consumption with age-related cognitive change // Neurology, 2006; 67:1370–1376.
90. Mueller S.G., Weiner M.W., Thal L.J. et al. The Alzheimer’s disease neuroimaging initiative. //In: Neuroimaging clinics of North America: Alzheimer’s disease: 100 years of progress. Petrella J.R., Doraiswamy P.M. (eds). Philadelphia: Elsevier Saunders. -2005. –P.869-877.
91. Nelson HD, Humphrey LL, Nygren P. et al. Postmenopausal hormone replacement therapy: scientific review. // JAMA 2002; 288:872–881
92. Olin J, Schneider L, Novit A, et al. Hydergine for dementia. // Cochrane Database Syst Rev, 2003:CD000359.
93. Orgogozo JM, Rigaud AS, Sto¨ffler A, Mo¨bius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). // Stroke. 2002;33:1834-1839.
94. Oswald W.D., Steyer W., Oswald B., Kuntz G. Die verbesserung fluider kognitiver leistungen als imdikator fur die klinishe wirksamkeit einer nootropen substanz. Eine placebokontrollierte doppelblind studie mit Actovegin. //Z. Gerontopsychol Psychiatric. –1991. –Bd4. –S.209-220
95. Palmer K., Backman L., Winblad B., Fratiglioni L. Mild cognitive impairment in general population: occurrence and progression to Alzheimer’s disease. //J Am Ger Psych. -2008. –V.16. –N.7. –P.603-611.
96. Panza F, Solfrizzi V, Frisardi V, et al. Diseasemodifying approach to the treatment of Alzheimer’s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators [review]. Drugs Aging. 2009;26(7):537-555.
97. Patterson C., Feightner J. W., Garcia A.et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease// Canadian Medical Association Journal, 2008; 178:548–556.
98. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704–715.
99. Petersen R. S., Smith G. E., Waring S. C. et al Mild cognitive impairment: clinical characterization and outcome // Arch. Neurol. – 1999. – Vol. 56. – P. 303-308.
100. Petersen R.C., Thomas R.G., Grundman N. et al. Donepizil and vitamin E in the treatment of mild cognitive impairment. //New Eng J Med. -2005. –V.352. –P.2379-2388.
101. Petersen R.C., Knopman D.S., Boeve B.F. et al. Mild cognitive impairment: 10 years later. //Arch Neurol. -2009. –V.66. –N.12. –P.1447-1455.
102. Petersen R.C. Early diagnosis of Alzheimer’s disease: is MCI too late? //Curr Alzheimer Res. -2009. –V.6. –N.4. –P. 324-330.
103. Pillon B., N.Gouider-Khonja, B.Deweer et al. Neuropsychological pattern of striatinigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. //J Neurol Neurosurg Psych. -1995. -V.58. -№ 2. -P. 174-179.
104. Plassman B.L., Langa K.M., Fisher G.G. et al. Prevalence of cognitive impairment without dementia in the United States. //Ann Neurol Med. -2008. –V.148. –N.6. –P. 427-434.
105. Plosker G.L., Gautheir S. Cere: a review of its use in dementia. Drugs Aging. -2009. –V.26. –N.11. –P.893-915.
106. Portet F., Ousset P.J., Visser P.J. et al. Mild cognitive impairment (MCI) in clinical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European consortium on Alzheimer’s disease //J Neurol Neurosurg Psychiat. -2006. -77. –P.714-718.
107. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient schaemic attack // Lancet 2001; 358: 1033 – 1041
108. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. // Ann Intern Med 2008;148:370-378.
109. Qiu C, von Strauss E, Fastbom J, et al. Low blood pressure and risk of dementia in the Kungsholmen Project. A 6-year follow-up study. // Arch Neurol 2003;60:223-228
110. Raschetti R., Albanese E., Vanacore N. et al. Maggini M. Cholinestarase ihibitors in MCI: a systematic review of randiomized trials. //PLoS Med. -2007. –V.4. –N.11. –e.338.
111. Roman G.V. Vascular dementia: NINDS - AIREN diagnostic criteria. //In: New concepts in vascular dementia. A.Culebras, J.Matias Guiu, G.Roman (eds). Barcelona: Prous Science Pub-lishers. -1993. -P.1-9.
112. Reisberg B., Ferris S.H., DeLeon M.J. et al. The global deterioration scale for assessment of primary degenerative dementia. //Am J Psychiatry. –1982. –V.139. –P.1136-1139.
113. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. //N Engl J Med. 2003;348:1333–1341
114. Reiman E. M., Langbaum J.BS., TarioP. N. Alzheimer’s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible // Biomark Med. 2010; 4: 3–14.
115. Roberts R.O., Geda Y.E., Knopman D. et al. The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. //Neuroepidemiology. -2008. –V.30. –P.58-69.
116. Sacco R. L., Adams R., Albers G. et al.Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline // Stroke. 2006; 37: 577 – 617.
117. Saletu B., Grunberger J., Linzmayer L. et al. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2 weeks infusions with the hemoderivative Actovegin: double blind placebo controlled trials. //Neuropsychobiol. –1990-91. –V.24. –P.135-145
118. Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? // Int J Neurosci. 2013; 123:444-449.
119. Scarmeas N, Stern Y, MayeuxR,Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. // Arch Neurol 2006;63:1709–1717
120. Scarmeas N., Stern Y., Mayeux R et al. Mediterranean diet and mild cognitive impairment. // Arch Neurol 2009;66:216–225
121. Schmage H., K.Boehme, J.Dycka, H.Schmitz. Nimodipine for psychogeriatric use: Methods, strategies, and considerations based on experience with clinical trials. //In: Diagnosis and treatment of senile dementia. M.Bergener, H.Reisberg (eds). -Berlin, Springer-Verlag. -1989. -P.374-381.
122. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. // JAMA. 2005; 294:1934-1943.
123. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. // Lancet. 2002;360:1623–1630.
124. Shumaker SA, Legault C, Kuller L, et al; Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. // JAMA 2004; 291:2947–2958.
125. Smith R.S., Vroulis R., Johnson et al. //Therapeutic response to long treatment of lecithin versus piracetam plus lecithin in AD patients. // Psychjpharmacol Bull.-1984. -V.20. –P.542-545.
126. Srikanth V.K., Quinn S.J., Donnan G.A., et al. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. // Stroke. 2006; 37:2479-2483.
127. Staessen J., Fagard R., Thijs L. Et al. Randomised double blind comparsion of placebo and active treatment for older patients with isolated systolic hypertension // Lancet 1997;350:757-764.
128. Szatmári S., Whitehouse P. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. -2003. - CD003119
129. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. // JAMA. 2004;291:317–324.
130. Thomas S. J., Grossberg GT Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias // Clinical Interventions in Aging 2009:4 367–377.
131. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. // JAMA. 2003; 290:2015-2022.
132. Unverzagt F.W., Gao S., Baiyewu O. et al. Prevalence of cognitive impairment: date from Indianapolis study of health and aging. //Neurology. -2001. –V.57. –P.1655-1662.
133. van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. // Am J Geriatr Psychiatry. 2006;14:428–437.
134. Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial Lancet Neurol. 2012; 11:851-859
135. Waegemans T, Wilsher CR, Danniau A. et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Disord. -2002. –V.13. –P.217-224.
136. Weinmann S., Roll S., Schwarzbach C. et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis// BMC Geriatrics 2010, 10:14
137. Weintraub D, Rosenberg PB, Drye LT et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. // Am J Geriatr Psychiatry2010;18:332–340.
138. Wechsler D. A standardized memory scale for clinical use. J of Psychology. -1945. –V.19. –P. 87-95.
139. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. N.Y., 1955
140. Wilcock G, Mo¨bius HJ, Sto¨ffler A; MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). // Int Clin Psychopharmacol. 2002;17:297–305.
141. Wilson R. S., Scherr P. A., Schneider J. A. et al. Relation of cognitive activity to risk of developing Alzheimer disease // Neurology, 2007; 69:1911–1920.
142. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/ aggression and psychosis in moderately severe to severe Alzheimer’s disase: a pooled analysis of 3 studies. // J Clin Psychiatry. 2008;69:341–348.
143. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). //Int J Geriatr Psychiatry. 1999;14:135–146.